Liquidia Corporation LQDA L606 — Program Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Liquidia Corporation in its filing.
Tagged under the XBRL concept lqda:ProgramExpenses.
The official record: Liquidia Corporation’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Liquidia Corporation's l606 — program expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Liquidia Corporation's l606 — program expenses?
- Liquidia Corporation (LQDA) reported l606 — program expenses of $5.82M in Q1 2026.
- How has Liquidia Corporation's l606 — program expenses changed year-over-year?
- Liquidia Corporation's l606 — program expenses increased by 78.2% year-over-year, from $3.27M to $5.82M.
- What is the long-term trend for Liquidia Corporation's l606 — program expenses?
- Over 2 years (2023 to 2025), Liquidia Corporation's l606 — program expenses has grown at a 25.2% compound annual growth rate (CAGR), from $12.55M to $19.68M.
- What does l606 — program expenses mean?
- This metric represents the direct research, development, and clinical trial costs specifically allocated to a single pharmaceutical product candidate or therapeutic program. It captures the capital intensity required to advance a specific drug through regulatory milestones and commercial readiness. Monitoring these expenses helps investors assess the company's investment commitment to its core pipeline assets.